SCHEMBL363343

SCHEMBL363343

O=Cc1ccc(NC(=O)c2ccccc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.67
NPC1 O15118 5/20 0.65
RAB9A P51151 5/20 0.65
SIRT1 Q96EB6 1/20 0.65
MEN1 O00255 1/20 0.65
KMT2A Q03164 1/20 0.65
KDM4E B2RXH2 1/20 0.65
POLB P06746 1/20 0.65
MAPT P10636 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
CACNA1B Q00975 1/20 0.61
APBA1 Q02410 1/20 0.61
PRMT1 Q99873 1/20 0.59
FFAR1 O14842 1/20 0.59
PGR P06401 1/20 0.59
JAK2 O60674 1/20 0.58
TYK2 P29597 1/20 0.58
CA12 O43570 1/20 0.57
CA2 P00918 1/20 0.57
CA9 Q16790 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL30758571 0.98 PTPN1 (0.65) PTPN1NPC1RAB9ASIRT1MEN1
SCHEMBL363882 0.93 PTPN1 (0.67) PTPN1NPC1RAB9ASIRT1MEN1
SCHEMBL16316028 0.90 NPC1 (0.59) PTPN1NPC1RAB9ASIRT1MEN1
SCHEMBL32688301 0.88 PTPN1 (0.77) PTPN1NPC1RAB9ASIRT1MEN1
SCHEMBL11772637 0.87 ALDH1A1 (0.68) PTPN1NPC1RAB9ASIRT1MEN1
SCHEMBL15652067 0.87 ALDH1A1 (0.68) PTPN1NPC1RAB9ASIRT1MEN1
SCHEMBL126415 0.86 PTPN1 (0.87) PTPN1NPC1RAB9ASIRT1MEN1
SCHEMBL27480739 0.84 UNG (0.56) PTPN1NPC1RAB9AMEN1KMT2A
SCHEMBL14715824 0.84 NPC1 (0.88) PTPN1NPC1RAB9ASIRT1MEN1
SCHEMBL18103163 0.84 NPC1 (0.88) PTPN1NPC1RAB9ASIRT1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416199-A1 INHIBITORS OF AMINO ACID TRANSPORT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-12-28 US disclosed
CN-110357789-B N-substituted acrylamide derivative as DHODH inhibitor and preparation and application thereof 华东理工大学 2022-09-30 CN disclosed
CN-111116464-B (E) -4- (pyridylformylhydrazono) -N-phenylbenzamide antitumor compounds 中国医科大学 2022-09-13 CN disclosed
WO-2022087630-A1 INHIBITORS OF AMINO ACID TRANSPORT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-04-28 WO disclosed
CN-111116464-A (E) -4- (pyridylformylhydrazono) -N-phenylbenzamide antitumor compounds 中国医科大学 2020-05-08 CN disclosed
EP-2417144-B1 SYNTHESIS OF 2'-O-FUCOSYLLACTOSE GLYCOM AS (DK) 2017-08-23 EP disclosed
EP-2417143-B1 SYNTHESIS OF 2'-O-FUCOSYLLACTOSE GLYCOM AS (DK) 2016-12-21 EP disclosed
US-20160024129-A1 SYNTHESIS OF NEW SIALOOLIGOSACCHARIDE DERIVATIVES GLYCOM A/S (DK) 2016-01-28 US disclosed
US-9200142-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-12-01 US disclosed
US-9200144-B2 Thermoplastic polymer composition MILLIKEN & COMPANY (US) 2015-12-01 US disclosed
EP-1340750-A1 AMIDE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-09-03 EP disclosed
WO-2003028762-A1 NOVEL ANTIMICROBIAL RESISTANCE BLOCKING COMPOSITIONS ETHICON, INC. (US) 2003-04-10 WO disclosed
EP-1165494-A2 HSV PRIMASE INHIBITORS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-01-02 EP disclosed
US-6323202-B1 BENZAMIDE SUBSTITUTES WITH KETONE COMPOUNDS AS ENZYME INHIBITORS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2001-11-27 US disclosed
WO-2000058270-A2 HSV PRIMASE INHIBITORS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2000-10-05 WO disclosed
EP-0784612-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-07-23 EP disclosed
WO-1996010559-A1 UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-04-11 WO disclosed
US-4933355-A ALDOSE REDUCTASE INHIBITORS SANKYO COMPANY LIMITED (JP) 1990-06-12 US disclosed
EP-0337819-A1 Thiazole derivatives, their preparation and their use in the treatment of diabetes complications Sankyo Company Limited (JP) 1989-10-18 EP disclosed
US-3931142-A Heterocyclic containing disazo compounds CIBA-GEIGY AG (CH) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024129-A1 SYNTHESIS OF NEW SIALOOLIGOSACCHARIDE DERIVATIVES FUCA1, FUT5, FUCA2 PTPN1 3558/4885NPC1 2003/4885RAB9A 823/4885
US-20230416199-A1 INHIBITORS OF AMINO ACID TRANSPORT SLC1A5, SLC7A1, SLC7A5 PTPN1 4141/4885NPC1 161/4885RAB9A 1245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.